Studie VERTIS‑CV

VÍTOVEC, Jiří, Lenka ŠPINAROVÁ and Jindřich ŠPINAR. Studie VERTIS‑CV (VERTIS-CV study). Remedia. Praha: Medical Tribune CZ, s.r.o., 2021, vol. 31, No 2, p. 154-155. ISSN 0862-8947.

Basic information

Original name

Studie VERTIS‑CV

Name (in English)

VERTIS-CV study

Authors

VÍTOVEC, Jiří (203 Czech Republic, guarantor, belonging to the institution), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution) and Jindřich ŠPINAR (203 Czech Republic, belonging to the institution)

Edition

Remedia, Praha, Medical Tribune CZ, s.r.o. 2021, 0862-8947

---

Other information

Language

Czech

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

RIV identification code

RIV/00216224:14110/21:00124450

Organization unit

Faculty of Medicine

Keywords (in Czech)

VERTIS‑CV

Keywords in English

VERTIS‑CV

Tags

rivok

Tags

Reviewed

---

Abstract

V originále

Studie VERTIS‑CV testovala účinnost inhibitoru sodíko‑glukózového kotransportéru 2 (SGLT2i) ertugliflozinu, který je indikován jako perorální antidiabetikum.

In English

The VERTIS-CV study tested the efficacy of the sodium-glucose cotransporter 2 (SGLT2i) inhibitor ertugliflozin, which is indicated as an oral antidiabetic agent.